EU Reveals Plan To Speed Development Of New COVID-19 Therapies
Project Includes A ‘Therapeutics Booster’ And R&D/Manufacturing Support
Executive Summary
Regulatory flexibilities such as rolling review, conditional marketing authorizations and possibly an EU emergency use authorization will play a key part in the EU’s plans to identify and approve promising new coronavirus treatments.
You may also be interested in...
Lenzilumab & Evusheld Make It Onto EU List Of ‘Most Promising’ COVID-19 Treatments
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
EU To Boost Portfolio Of Potential COVID-19 Treatments
The European Commission has set up a new expert group on virus variants whose tasks will include selecting the criteria for identifying possible new treatments and vaccines for COVID-19.
May 2021 Update: EU/UK Coronavirus Vaccine And Treatment Progress At A Glance
Rolling reviews are now in progress at the European Medicines Agency for four COVID-19 vaccines and for four potential COVID-19 treatments.